Intrathecal Analagesic Delivery System
An intrathecal analgesic delivery system is one approach that is a step above the WHO ladder (see Figure 1 ). In their cancer pain guidelines, the American Cancer Society and National Comprehensive Cancer Network (2000) noted the need for this therapy to be considered. In a randomized clinical trial of more than 200 patients with cancer that examined comprehensive medical pain management versus intrathecal drug delivery systems, drug toxicity decreased and pain relief improved when using intrathecal drug delivery systems (Smith et al., 2002) . The ideal candidates for intrathecal analgesia are those continuing to experience refractory pain or those experiencing symptoms from analgesic agents themselves (see Figures 2 and 3 ).
Institutional Requirements
The use of intrathecal therapy has been accepted as an integral system for managing pain. This intervention must be considered and offered in the case of refractory pain or for symptoms from analgesic agents (Smith, Coyne, & Staats, 2004) . Typically, intrathecal therapy can be managed easily in the outpatient setting (Smith & Coyne, 2003) . Nurses must be trained and supported adequately to provide seamless patient care with minimal risk of complications. A multidisciplinary approach is required to ensure appropriate analgesia. Knowledgeable physicians, nurses, pharmacists, and physical and occupational therapists, as well as appropriate psychosocial support, are important to properly manage pain in this population (Panke & Coyne, 2004 Psychosocial support is critical because this population typically has experienced severe pain and/or symptoms for a considerable period; therefore, depression and anxiety are not uncommon. Patients and their families will need support. At the Massey Cancer Center in Richmond, VA, nurses receive specialized training for pump interrogation, dose changes, and emergency stoppage of the pump. A small group of nurses receives additional training followed by validation of skills for pump refi ll. All staff calculations are confi rmed independently by another trained staff member, and two nurses perform each refi ll (Coyne, Hansen, Laird, Buster, & Smith, 2004) . Policies, critical pathways, and algorithms are requirements for initiating, managing, and standardizing intrathecal therapy (Coyne & Du Pen, 2003) . Appropriate knowledge, training, and experience are essential for pump management. See Figure 4 for an example of a protocol.
The Massey Cancer Center has developed a patient management system that enables patients to visit the outpatient clinic daily for intrathecal pump titration or refi lls. No appointments are required; however, they are requested. For after-hours support, the Thomas Palliative Care Unit nursing staff, an inpatient unit in the institution, provides emergency titration. The Massey Cancer Center has supported partnerships with local hospices and rural hospitals to make intrathecal therapy available in community and rural settings. These partnerships decrease the need for lengthy travel while improving analgesia and symptom management.
Titration Guidelines
The initial opioid dose (always preservative free) should be calculated from the epidural trial dose that helped the patient achieve comfort. Conduct a one-to two-day epidural trial seeking at least a 50% improvement in pain and/or symptoms while encouraging improved function with physical and occupational therapists (Coyne, 2003) . The intrathecal hourly dose is typically 10% of the epidural hourly dose. Preservative-free morphine, the only opioid approved by the U.S. Food and Drug Administration for this use, is the opioid of choice because of its hydrophilic nature, which allows a greater spread of opioid within the spine; however, 
FIGURE 1. TYPICAL PLACEMENT OF AN INTRATHECAL PUMP IN THE LATERAL ABDOMINAL WALL, WITH THE CATHETER TUNNELED AROUND AND INSERTED IN THE THECAL SAC
• More conservative therapies have failed.
-Inadequate pain relief despite aggressive analgesic titration -Unacceptable side effects
• Patient consent -Implant -Refi lls or titration -Travel may be required.
• Physician is able to manage the patient (or partner with pain specialist).
• No active infection or anticipated need for anticoagulant therapy
FIGURE 2. INTRASPINAL THERAPY PATIENT SELECTION: GENERAL
Note. Based on information from Smith & Coyne, 2003 .
• Chronic pain because of cancer, or therapy intolerable to the patient
• Life expectancy more than three months
• Pain resistant to aggressive therapy
• Round-the-clock dosing and as needed -Nonsteroidal anti-infl ammatory drugs, opioids, neuroleptics, antidepressants, etc. -Oral, IV, or transdermal infusion with external pump
• High doses of systemic opioids
• Favorable response to intraspinal morphine screening trial
• No contraindications for pump implant
FIGURE 3. INTRASPINAL THERAPY PATIENT SELECTION: CANCER PAIN
Note. Based on information from Portenoy & Lesage, 1999; Smith & Coyne, 2003. hydromorphone also may be used. Other analgesic agents typically are utilized when pain, such as neuropathic pain, does not respond well to opioids. At the Massey Cancer Center, approximately 40% of patients with cancer require more than one medication, with a small percentage requiring three or more. These guidelines are designed to be a resource; individual patient needs may vary to achieve comfort. Follow all refi ll titration policies and procedures .
Summary
Options other than those described by the WHO analgesic ladder must be available to ensure comfort with chronic, often painful illnesses such as cancer. Invasive techniques, including epidural and intrathecal therapies, must become readily available to this population of patients. While this change in analgesic practice occurs, appropriate and safe treatment modalities must be established.
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Rapid Recap Effectively Starting and Titrating Intrathecal Analgesic Therapy in Patients With Refractory Cancer Pain
• A population of patients with cancer suffers from intractable cancer pain and/or symptoms despite aggressive analgesic management.
• Intrathecal analgesic therapy may serve as an appropriate intervention for pain control.
• Although intrathecal analgesic therapy is not new, many oncology clinicians are not familiar with its benefi ts or techniques for titration. 
FIGURE 4. INTRATHECAL TITRATION GUIDELINES

